Metraipolis › archive › dc_329d6337fd9d
Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41704755
- DOI
- 10.1016/j.isci.2026.114766
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T15:20:55.281Z
- SHA-256 of the archived text
cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6- Stable URL of this page
https://metraipolis.com/documento/dc_329d6337fd9d
How to cite
Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755 — Europe PMC (en), https://europepmc.org/article/MED/41704755 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_329d6337fd9d (Metraipolis archive dc_329d6337fd9d, sha256 cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6)
BibTeX
@misc{dc329d6337fd9d,
title = {Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41704755},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_329d6337fd9d; sha256 cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41704755. Agents can read the archived copy with the MCP tool read_document.